Literature DB >> 7534187

Modulation of dopamine and noradrenaline release and of intracellular Ca2+ concentration by presynaptic glutamate receptors in hippocampus.

J O Malva1, A P Carvalho, C M Carvalho.   

Abstract

1. We studied the release of [3H]-dopamine and [3H]-noradrenaline (NA) from hippocampal synaptosomes induced by glutamate receptors and the associated Ca2+ influx through Ca2+ channels. The release of tritiated neurotransmitters was studied by use of superfusion system and the intracellular free Ca2+ concentration ([Ca2+]i) was determined by a fluorimetric assay with Indo-1 as a probe for Ca2+. 2. Presynaptic glutamate receptor activation induced Ca(2+)-dependent release of [3H]-dopamine and [3H]-NA from rat hippocampal synaptosomes. Thus, L-glutamate induced the release of both neurotransmitters in a dose-dependent manner (EC50 = 5.62 microM), and the effect of 100 microM L-glutamate was inhibited by 83.8% in the presence of 10 microM 6-cyano-7-nitroquinoxaline-2,3-dioxine (CNQX), but was not affected by 1 microM (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK-801). 3. Other glutamate receptor agonists also stimulated the Ca(2+)-dependent release of [3H]-dopamine and [3H]-NA as follows: N-methyl-D-aspartate (NMDA), at 200 microM, released 3.65 +/- 0.23% of the total 3H catecholamines, and this effect was inhibited by 81.2% in the presence of 1 microM MK-801; quisqualate (50 microM), S-alpha-amino-3-hydroxy-5-methyl-4-isoxazolopropionic acid (AMPA) (100 microM) or kainate (100 microM) released 1.57 +/- 0.26%, 1.93 +/- 0.17% and 2.09 +/- 0.22%, of the total 3H catecholamines, respectively. 4. The ionotropic glutamate receptor agonist, AMPA, induced an increase in the [Ca2+]i which was inhibited by 58.6% in the presence of 10 microM CNQX. In contrast, the increase in [Ca2+]i due to stimulation by glutamate was not sensitive to CNQX or MK-801.5. Nitrendipine, at I JAM, did not inhibit the neurotransmitter release induced by AMPA, but, both 0.5 micro M -conotoxin GVIA (w-CgTx) and 100 nM w-Aga IVA reduced catecholamine release to 49.03 +/- 3.79% and 46.06 +/- 10.51% of the control, respectively. In the presence of both toxins the release was reduced to 12.58 +/- 4.64% of the control.6. The results indicate that activation of presynaptic glutamate receptors of the NMDA and non-NMDA type induces the release of [3H]-dopamine and [H]-NA from rat hippocampal synaptosomes and that the release induced by AMPA involves the activation of N- and P-type Ca2" channels which allow the influx of Ca2" that triggers the 3H catecholamines release.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7534187      PMCID: PMC1510498          DOI: 10.1111/j.1476-5381.1994.tb17158.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Release of endogenous norepinephrine from rat hypothalamus by stimulation of N-methyl-D-aspartic acid receptors.

Authors:  P Blandina; D Johnson; J Walcott; J Goldfarb
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

2.  Calcium channels coupled to glutamate release identified by omega-Aga-IVA.

Authors:  T J Turner; M E Adams; K Dunlap
Journal:  Science       Date:  1992-10-09       Impact factor: 47.728

3.  A toxin fraction (FTX) from the funnel-web spider poison inhibits dihydropyridine-insensitive Ca2+ channels coupled to catecholamine release in bovine adrenal chromaffin cells.

Authors:  C B Duarte; L M Rosario; C M Sena; A P Carvalho
Journal:  J Neurochem       Date:  1993-03       Impact factor: 5.372

4.  Effects of stimulus intensity on the inhibition by omega-conotoxin GVIA and neomycin of K(+_-evoked [3H]norepinephrine release from hippocampal brain slices and synaptosomal calcium influx.

Authors:  R A Keith; M B Horn; T M Piser; T J Mangano
Journal:  Biochem Pharmacol       Date:  1993-01-07       Impact factor: 5.858

Review 5.  Excitatory amino acid action on the release of brain neurotransmitters and neuromodulators: biochemical studies.

Authors:  B B Ruzicka; K H Jhamandas
Journal:  Prog Neurobiol       Date:  1993-02       Impact factor: 11.685

6.  A simple apparatus for studying the release of neurotransmitters from synaptosomes.

Authors:  M Raiteri; F Angelini; G Levi
Journal:  Eur J Pharmacol       Date:  1974-03       Impact factor: 4.432

7.  Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes. Clues to the locus of action.

Authors:  H T McMahon; P Foran; J O Dolly; M Verhage; V M Wiegant; D G Nicholls
Journal:  J Biol Chem       Date:  1992-10-25       Impact factor: 5.157

8.  Effects of L- and N-type Ca2+ channel antagonists on excitatory amino acid-evoked dopamine release.

Authors:  I Chaudieu; R Alonso; H Mount; R Quirion; P Boksa
Journal:  Eur J Pharmacol       Date:  1992-09-22       Impact factor: 4.432

Review 9.  Properties of vertebrate glutamate receptors: calcium mobilization and desensitization.

Authors:  C F Zorumski; L L Thio
Journal:  Prog Neurobiol       Date:  1992-09       Impact factor: 11.685

10.  Endogenous noradrenaline and dopamine in nerve terminals of the hippocampus: differences in levels and release kinetics.

Authors:  M Verhage; W E Ghijsen; F Boomsma; F H Lopes da Silva
Journal:  J Neurochem       Date:  1992-09       Impact factor: 5.372

View more
  8 in total

1.  Synergistically interacting dopamine D1 and NMDA receptors mediate nonvesicular transporter-dependent GABA release from rat striatal medium spiny neurons.

Authors:  A N Schoffelmeer; L J Vanderschuren; T J De Vries; F Hogenboom; G Wardeh; A H Mulder
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

Review 2.  Regulation of vesicle traffic and neurotransmitter release in isolated nerve terminals.

Authors:  Wim E J M Ghijsen; A G Miriam Leenders; Fernando H Lopes da Silva
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

3.  Immuno-Pharmacological Characterization of Presynaptic GluN3A-Containing NMDA Autoreceptors: Relevance to Anti-NMDA Receptor Autoimmune Diseases.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Cesare Usai; Anna Pittaluga
Journal:  Mol Neurobiol       Date:  2019-02-07       Impact factor: 5.590

4.  Differentiation of sigma ligand-activated receptor subtypes that modulate NMDA-evoked [3H]-noradrenaline release in rat hippocampal slices.

Authors:  F P Monnet; B R de Costa; W D Bowen
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

5.  Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.

Authors:  E Luccini; V Musante; E Neri; M Brambilla Bas; P Severi; M Raiteri; A Pittaluga
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

6.  CXCR4 and NMDA Receptors Are Functionally Coupled in Rat Hippocampal Noradrenergic and Glutamatergic Nerve Endings.

Authors:  Silvia Di Prisco; Guendalina Olivero; Elisa Merega; Tommaso Bonfiglio; Mario Marchi; Anna Pittaluga
Journal:  J Neuroimmune Pharmacol       Date:  2016-05-05       Impact factor: 4.147

7.  Norepinephrine transporter antagonism prevents dopamine-dependent synaptic plasticity in the mouse dorsal hippocampus.

Authors:  Alex Sonneborn; Robert W Greene
Journal:  Neurosci Lett       Date:  2020-10-27       Impact factor: 3.046

Review 8.  Presynaptic release-regulating NMDA receptors in isolated nerve terminals: A narrative review.

Authors:  Anna Pittaluga
Journal:  Br J Pharmacol       Date:  2021-02-02       Impact factor: 9.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.